Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D Head Sean Harper On Amgen's Long-Term Investment View

Executive Summary

Amgen is validating targets through the deCODE Genetics investment it made five years and moving drugs into the clinic. It's one of multiple technologies – along with its BiTE and oncolytic virus platforms – that R&D head Sean Harper said is starting to bear fruit for the company.

Advertisement

Related Content

Harper, Hooper Exit As Amgen Revenues Rise
Harper, Hooper Exit As Amgen Revenues Rise
Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration
Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III
Amgen's Imlygic 1st FDA-Approved Oncolytic Virus Therapy
Amgen hangs on to Kite in CAR-T race
Amgen gains early US win for BiTE antibody Blincyto
'Beautiful baton pass' as Amgen picks up deCODE to validate drug targets
Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour
Amgen beats the street and announces $425M cancer vaccine maker purchase

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100481

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel